Search research articles
Contact Us
Filters
Showing results (51-60 of 61) with videos related to
Page
of 7
Sort By:
Journal of the American Heart Association
|
December 11, 2019
Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart
Junhui Sun, Weidong Hao, Natasha Fillmore, et al.
Cancer Immunology, Immunotherapy : CII
|
March 2, 2024
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma
Tanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 13, 2025
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
Patricia McCoon, Ying Wang, Zhongwu Lai, et al.
Cancer Management and Research
|
December 11, 2019
A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer
Matthew B Schabath, Tapashi B Dalvi, Hongyue A Dai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2022
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Gilberto de Castro, Naiyer A Rizvi, Peter Schmid, et al.
Molecular Cancer Therapeutics
|
May 15, 2020
Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive Cells
Ruoyan Chen, Saravanan Rajan, Michael G Overstreet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 4, 2016
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 11, 2024
Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC
Tae Hee Hong, Soohyun Hwang, Abhijit Dasgupta, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
August 15, 2019
Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray
Sandra Martinez-Morilla, John McGuire, Patricia Gaule, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sophie Wildsmith, Weimin Li, Song Wu, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 61) with videos related to
Sort By:
Page
of 7
Journal of the American Heart Association
|
December 11, 2019
Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart
Junhui Sun, Weidong Hao, Natasha Fillmore, et al.
Cancer Immunology, Immunotherapy : CII
|
March 2, 2024
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma
Tanguy Y Seiwert, Sophie Wildsmith, Jérôme Fayette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 13, 2025
Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes
Patricia McCoon, Ying Wang, Zhongwu Lai, et al.
Cancer Management and Research
|
December 11, 2019
A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer
Matthew B Schabath, Tapashi B Dalvi, Hongyue A Dai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2022
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Gilberto de Castro, Naiyer A Rizvi, Peter Schmid, et al.
Molecular Cancer Therapeutics
|
May 15, 2020
Preclinical Characterization of an Antibody-Drug Conjugate Targeting CS-1 and the Identification of Uncharacterized Populations of CS-1-Positive Cells
Ruoyan Chen, Saravanan Rajan, Michael G Overstreet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 4, 2016
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R Hirsch, Abigail McElhinny, Dave Stanforth, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 11, 2024
Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC
Tae Hee Hong, Soohyun Hwang, Abhijit Dasgupta, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
August 15, 2019
Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray
Sandra Martinez-Morilla, John McGuire, Patricia Gaule, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sophie Wildsmith, Weimin Li, Song Wu, et al.
Page
of 7